InVivo Therapeutics Holdings Corp., a research and clinical-stage biomaterials and biotechnology company, engages in developing and commercializing biopolymer scaffolding devices for the treatment of spinal cord injuries. It is developing Neuro-Spinal Scaffold implant, an investigational bioresorbable polymer scaffold for implantation at the site of injury within a spinal cord. InVivo Therapeutics Holdings Corp. has research collaboration with the Q Therapeutics, Inc. for the evaluation of the combination of PLGA-PLL based Neuro-Spinal Scaffold with adult neural progenitor cells, including those from induced pluripotent stem cells. The company was founded in 2005 and is headquartered in Cambridge, Massachusetts.
Industry, Sector and Symbol
Industry Surgical & medical instruments
Sub-IndustryN/A
SectorMedical
Phone617-863-5500
Debt
Price-To-Earnings
Sales & Book Value
Annual SalesN/A
Profitability
Miscellaneous
EmployeesN/A
Next Earnings Date3/25/2019 (Estimated)
OptionableNot Optionable
Invivo Therapeutics (NASDAQ:NVIV) Frequently Asked Questions
What is Invivo Therapeutics' stock symbol?
Invivo Therapeutics trades on the NASDAQ under the ticker symbol "NVIV."
When did Invivo Therapeutics' stock split? How did Invivo Therapeutics' stock split work?
Invivo Therapeutics shares reverse split before market open on Tuesday, April 17th 2018. The 1-25 reverse split was announced on Monday, April 9th 2018. The number of shares owned by shareholders was adjusted after the market closes on Monday, April 16th 2018. An investor that had 100 shares of Invivo Therapeutics stock prior to the reverse split would have 4 shares after the split.
How were Invivo Therapeutics' earnings last quarter?
Invivo Therapeutics Holdings Corp (NASDAQ:NVIV) released its quarterly earnings data on Tuesday, August, 7th. The biotechnology company reported ($7.48) earnings per share for the quarter, missing the consensus estimate of ($0.41) by $7.07. View Invivo Therapeutics' Earnings History.
When is Invivo Therapeutics' next earnings date?
Has Invivo Therapeutics been receiving favorable news coverage?
News coverage about NVIV stock has been trending somewhat negative on Saturday, according to InfoTrie. The research group identifies positive and negative press coverage by analyzing more than six thousand news and blog sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Invivo Therapeutics earned a media sentiment score of -1.4 on InfoTrie's scale. They also gave press coverage about the biotechnology company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an impact on the company's share price in the next few days.
Who are some of Invivo Therapeutics' key competitors?
Some companies that are related to Invivo Therapeutics include Pro-Dex (PDEX), Repro-Med Systems (REPR), RA Medical Systems (RMED), AIT Therapeutics (AITB), Obalon Therapeutics (OBLN), Avinger (AVGR), Valeritas (VLRX), Hancock Jaffe Laboratories (HJLI), Nephros (NEPH), Restoration Robotics (HAIR), PAVmed (PAVM), DarioHealth (DRIO), Lianluo Smart (LLIT), SANUWAVE Health (SNWV) and Interpace Diagnostics Group (IDXG).
What other stocks do shareholders of Invivo Therapeutics own?
Who are Invivo Therapeutics' key executives?
Invivo Therapeutics' management team includes the folowing people:
- Dr. Richard M. Toselli, Pres, CEO, Chief Medical Officer & Director (Age 61)
- Dr. Robert S. Langer Jr., Co-Founder & Member of Scientific Advisory Board (Age 70)
- Dr. Joseph Philip Vacanti, Co-Founder (Age 70)
- Mr. Richard C. Christopher, Chief Financial Officer (Age 49)
- Mr. William D'Agostino PE, Sr. VP of Operations
Who are Invivo Therapeutics' major shareholders?
Which major investors are buying Invivo Therapeutics stock?
How do I buy shares of Invivo Therapeutics?
Shares of NVIV can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Invivo Therapeutics' stock price today?
One share of NVIV stock can currently be purchased for approximately $1.69.
How big of a company is Invivo Therapeutics?
Invivo Therapeutics has a market capitalization of $15.73 million. The biotechnology company earns $-26,740,000.00 in net income (profit) each year or ($18.50) on an earnings per share basis.
What is Invivo Therapeutics' official website?
How can I contact Invivo Therapeutics?
Invivo Therapeutics' mailing address is ONE KENDALL SQUARE SUITE B14402, CAMBRIDGE MA, 02139. The biotechnology company can be reached via phone at 617-863-5500 or via email at [email protected]
MarketBeat Community Rating for Invivo Therapeutics (NASDAQ NVIV)
MarketBeat's community ratings are surveys of what our community members think about Invivo Therapeutics and other stocks. Vote "Outperform" if you believe NVIV will outperform the S&P 500 over the long term. Vote "Underperform" if you believe NVIV will underperform the S&P 500 over the long term. You may vote once every thirty days.
